Article Text

Download PDFPDF
Reversible male infertility under treatment with an anti-TNFα agent: a case report
  1. Lukas M Wildi,
  2. Boulos Haraoui
  1. Department of Rheumatology, University of Montreal Hospital Centre (CHUM), Montreal, Quebec, Canada
  1. Correspondence to Lukas M Wildi, Department of Rheumatology, University of Montreal Hospital Centre (CHUM), Notre-Dame Hospital, 1560, Sherbrooke Street East, Montreal, QC H2L 4M1, Canada; lukas.wildi{at}gmx.com

Statistics from Altmetric.com

More than a decade of use of the anti-tumour necrosis factor (anti-TNF) agents in rheumatology has confirmed their acceptable safety profile and very few new rare side effects have emerged. However, TNFα, a pleiotropic cytokine, is important to many physiological functions and its suppression may lead to unexpected consequences. We describe here a rare case of reversible oligoasthenozoospermia in a young patient.

Case report

This case concerns a 35-year-old father of a healthy 4-year-old child who was successfully treated for 3 years with adalimumab, a monoclonal human antibody against TNFα, 40 mg subcutaneously every 2 weeks for ankylosing spondylitis (AS). The therapy …

View Full Text

Footnotes

  • Competing interests None.

  • Ethics approval This letter reports a case of an ankylosing spondylitis patient treated according to the current guidelines. Personal data remain completely anonymous.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.